Elevating the field for applying neuroimaging to individual patients in psychiatry

• Published in: Translational psychiatry Vol. 14; no. 1; pp. 87 - 12
• Main Authors: Roalf, David R., Figee, Martijn, Oathes, Desmond J.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.02.2024; Nature Publishing Group
• Subjects: 59/36; 59/57; 631/378; 692/53/2422; 692/53/2423; 692/699/476; Behavioral Sciences; Biological Psychology; Expert Review; Medical imaging; Medicine; Medicine & Public Health; Neuroimaging; Neurosciences; Pharmacotherapy; Psychiatry
• ISSN: 2158-3188; 2158-3188
• DOI: 10.1038/s41398-024-02781-7

Although neuroimaging has been widely applied in psychiatry, much of the exuberance in decades past has been tempered by failed replications and a lack of definitive evidence to support the utility of imaging to inform clinical decisions. There are multiple promising ways forward to demonstrate the relevance of neuroimaging for psychiatry at the individual patient level. Ultra-high field magnetic resonance imaging is developing as a sensitive measure of neurometabolic processes of particular relevance that holds promise as a new way to characterize patient abnormalities as well as variability in response to treatment. Neuroimaging may also be particularly suited to the science of brain stimulation interventions in psychiatry given that imaging can both inform brain targeting as well as measure changes in brain circuit communication as a function of how effectively interventions improve symptoms. We argue that a greater focus on individual patient imaging data will pave the way to stronger relevance to clinical care in psychiatry. We also stress the importance of using imaging in symptom-relevant experimental manipulations and how relevance will be best demonstrated by pairing imaging with differential treatment prediction and outcome measurement. The priorities for using brain imaging to inform psychiatry may be shifting, which compels the field to solidify clinical relevance for individual patients over exploratory associations and biomarkers that ultimately fail to replicate.